Increasing FTD Drug Development Grants and Funding by Non-Profit Organisations
Non-profit organizations, disease advocacy and private organizations currently are focusing on to support the frontotemporal disorders treatment drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organization such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, CurePSP, Inc. have helped to promote frontotemporal disorders treatment drugs research initiatives.
Growing Prevalence of Dementia Expected to Propel the Demand for Frontotemporal Disorders Treatment Drugs
Dementia affects around 50 million people globally. Frontotemporal dementia may account for 2–5% of the overall dementia cases. Dementia prevalence is projected to nearly triple by 2050. According to the Dementia Statistics Organization, globally the number of people living with dementia will increase by 204% from 50 Mn in 2018 to 152 Mn in 2050.
The growing number of dementia cases will also increase the population base of frontotemporal dementia, which is expected to propel the demand for frontotemporal disorders treatment drugs and medications.
Orphan Drug Development Incentives by FDA Expected to Increase Drug Developer Interest Towards Frontotemporal Disorders Treatment Drug Development
Frontotemporal dementia falls under the rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under the auspices of Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in the Europe. Orphan drug designation to FTD allows the continuation of clinical trial and drug development with commercial incentives, prioritized consultation by FDA on clinical studies and reduction in regulatory fees
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
High Life Expectancy Rate Leads to Higher Prevalence of Frontotemporal Disorders in the Older Age Group
Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to high prevalence of frontotemporal disorder among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such frontotemporal disorder, Alzheimer and dementia. The global population is projected to increase over the time.
Global population in 2015 was around 7.2 Bn and is estimated to grow to around 15 Bn in 2050. People aged 65 and above is one of the fast growing demographics across the globe. Frontotemporal dementia affects around 6.5 people in 100,000 over the age of 65 annually.
This section of the report features profiles of the key players operating in the frontotemporal disorders treatment market based on their market shares, differential strategies, product offerings, marketing approach, and company dashboard.
Examples of some of the frontotemporal disorders treatment market key players featured in this report includes Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, GlaxoSmithKline Plc., Novartis AG, Mylan N.V., Merck & Company, Inc., AstraZeneca plc., and Allergen plc, among others. Many companies in the frontotemporal disorders treatment market are aiming on clinical studies and trials for new drug development.
Frontotemporal disorders are a bunch of rare disorders that include shrinkage of particular portion of the brain, which controls personality, language, and behavior. The condition rises due to degeneration of frontotemporal cells, which are named as frontotemporal lobar degeneration (FTLD). The typical age range for onset of frontotemporal dementia is 40 to 60 years of age, however, it can start after 60 years of age and the maximum life expectancy after diagnosis is 8–10 years.
About the Report
The company conducted a research study on the frontotemporal disorders treatment market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the frontotemporal disorders treatment market along with insights on the market dynamics, market trend and opportunities, pipeline analysis, disease epidemiology and others. The frontotemporal disorders treatment market report elaborates the macroeconomic factors influencing the dynamics of frontotemporal disorders treatment market and its futuristic potential.
Additional Questions Answered
Some of the additional questions addressed in this report on the frontotemporal disorders treatment market-
- Who are the key competitors and their product portfolio and strategy in frontotemporal disorders treatment market?
- What are major challenges influencing the growth of frontotemporal disorders treatment market?
- What are major trends in the frontotemporal disorders treatment market?
The frontotemporal disorders treatment market has been estimated based on epidemiology-based model and adoption of different symptomatic drugs. The market value was first calculated based on epidemiology of frontotemporal dementia in different region/countries. The frontotemporal disorders treatment market value was estimated based on adoption of different drugs for behavioral and psychological symptoms management, pricing analysis, and epidemiology in top 20 countries globally.
Other qualitative factors analyzed are pipeline analysis, regulatory policies, neurological healthcare expenditure related to frontotemporal disorders treatment. This information is further validated with rigorous primary research (including in-person interactions, interviews, surveys and viewpoints of seasoned analysts) and secondary research (including authentic trade journals, verified paid sources and resourceful databases).
The research study on frontotemporal disorders treatment market also includes top trends and macro as well as microeconomic factors shaping the frontotemporal disorders treatment market. With this approach, the report on frontotemporal disorders treatment market anticipates the industry attractiveness of every major segment in frontotemporal disorders treatment over the forecast period.
The report offers a comprehensive taxonomy of the frontotemporal disorders treatment market based on drug class, treatment type, disease indication, distribution channel and region. By drug class, the frontotemporal disorders treatment market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. By treatment type, the frontotemporal disorders treatment market is segmented into behavioral symptom management and psychological symptoms management segment.
By disease indication, the frontotemporal disorders treatment market is segmented into frontotemporal dementia, primary progressive aphasia, and movement disorders segment. By distribution channel, the frontotemporal disorders treatment market is segmented into hospital pharmacies, retail pharmacy, drug stores and online pharmacy.
The frontotemporal disorders treatment market has been analyzed across seven regions including North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan (APEJ), Japan and Middle East & Africa (MEA).